Letter from the Editors.
Sathekge MM, Bouchelouche K.
Semin Nucl Med. 2020 Mar;50(2):115-117. doi: 10.1053/j.semnuclmed.2020.02.014.
Alpha-particles and leukaemia.
Mole RH.
Nature. 1992 Jun 4;357(6377):369-70. doi: 10.1038/357369b0.
Alpha particle leukaemogenesis.
Mole RH.
Lancet. 1990 Apr 14;335(8694):919-20. doi: 10.1016/0140-6736(90)90521-6.
Patient-specific alpha-particle dosimetry.
Palm S, Elgqvist J, Jacobsson L.
Curr Radiopharm. 2011 Oct;4(4):329-35. doi: 10.2174/1874471011104040329.
Targeted alpha-Emitter Therapy of Neuroendocrine Tumors.
Kunikowska J, Królicki L.
Semin Nucl Med. 2020 Mar;50(2):171-176. doi: 10.1053/j.semnuclmed.2019.11.003.
Targeted Alpha Therapy: Current Clinical Applications.
Guerra Liberal FDC, O'Sullivan JM, McMahon SJ, Prise KM.
Cancer Biother Radiopharm. 2020 Aug;35(6):404-417. doi: 10.1089/cbr.2020.3576. Epub 2020 Jun 16.
Why bother with alpha particles?
King AP, Lin FI, Escorcia FE.
Eur J Nucl Med Mol Imaging. 2021 Dec;49(1):7-17. doi: 10.1007/s00259-021-05431-y. Epub 2021 Jun 27.
Alpha-particles for targeted therapy.
Sgouros G.
Adv Drug Deliv Rev. 2008 Sep;60(12):1402-6. doi: 10.1016/j.addr.2008.04.007. Epub 2008 Apr 23.
Helium 4He nuclei based radiotherapy.
Knake N, Prokopowicz R, Gryziński MA, Kocik J.
Appl Radiat Isot. 2025 Nov;225:112068. doi: 10.1016/j.apradiso.2025.112068. Epub 2025 Jul 23.
Alpha-ray activity in coronary artery disease.
Elkeles A.
J Am Geriatr Soc. 1968 May;16(5):576-83. doi: 10.1111/j.1532-5415.1968.tb02098.x.
